bioAffinity Technologies Inc (BIAF)

[Zardiw]

#DDAmanda Video - $BIAF - Gain: +292% Video Analysis - #1 Stock Screener / Scanner

Z

[subslover]

YES! We will break $2😷

[Stockexpertpro]

HEPA Low Float Bio Tech under cash heavy short like RSLS ICCT

[Gator44]

Halted $1.45 can we get $2

[Gator44]

Halted $1.45 can we get $2

[Gator44]

$$$ Dollar land nice volume $$$

[subslover]

Insane volume! Won't stay under $1.00 much longer!😛

[glenn1919]

BIAF.................................................p/m

[knrorrel]

will $BIAF go to $2.27 today, just like icct did yesterday? The only difference is that ICCT had no news and went up to $2.27, and $BIAF released super news with a huge increase in profits and a great, bright future last night. $BIAF has a much better structure (than icct), the chart is at rock bottom, and the news could be the start of a major reversal, and the market capitalization is low.
Therefore, the potential is even higher than $2.27, imho.
🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥

[knrorrel]

https://www.stockscores.com/charts/charts/?ticker=Biaf This fantastic, surprising news is likely the starting signal for a huge turnaround and a major rise. The market capitalization is far too small, and the potential far too great.... A $BIAF explosion above the dollar is definitely coming, imho

https://stockcharts.com/sc3/ui/?s=BIAF

[knrorrel]

This is really very good news, such fantastic news like this is released to the market far too rarely and I hope we have a multi-day multi-DOLLAR runner here with $BIAF


imho

[subslover]

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
Increased Demand, Expanded Insurance Coverage Drive Record Growth

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the year ended December 31, 2024.

2024 Highlights

Record Revenue: Revenue grew approximately 270% to $9.4 million in 2024, a significant increase from $2.5 million in 2023.
Increased Demand: CyPath® Lung orders grew by approximately 1,400% over full-year 2023, reflecting increasing physician adoption.
CyPath® Lung Reimbursed by Medicare and Private Insurance: The unique CPT code for CyPath® Lung was added to the Centers for Medicare and Medicaid Services (CMS) 2024 clinical laboratory schedule effective January 1, leading to reimbursement of the test by both Medicare and private insurers.
Expanded Physician Network: Number of physician offices signed increased by over 300% in 2024, positioning the Company for continued growth in 2025.
Federal Supply Schedule (FSS) Listing: In October 2024, CyPath® Lung was added to the U.S. Federal Supply Schedule, granting Veterans Health Administration and Military Health System facilities streamlined access to the test. Through 1,380 government healthcare facilities, Veterans at high risk for developing lung cancer can now benefit from CyPath® Lung.
Economic Validation: A study published in the Journal of Health Economics and Outcomes Research concluded that adding CyPath® Lung to the standard of care for Medicare patients with a positive lung cancer screening could have saved an average of $2,773 per patient, amounting to $379 million in total cost savings in 2022. The savings for private insurance patients would have been even greater, an average of $6,460 per patient, an estimated total savings of $895 million if all individuals screened in 2022 were covered by private insurance.
Leadership Appointments: Appointed J. Michael Edwards, CPA, MBA, as Chief Financial Officer. He previously served bioAffinity Technologies as consulting Chief Financial Officer until 2023 and rejoined the management team to help oversee the long-term financial and strategic direction of the Company, including the ongoing commercialization of CyPath® Lung. Appointed William Bauta, PhD, as Chief Science Officer. Bauta joined bioAffinity Technologies as Senior Vice President in 2016. He previously served as Associate Director of Science at Genzyme.
Innovation Pipeline Progress: Company scientists are developing diagnostic tests for Chronic Obstructive Pulmonary Disease (COPD) and asthma that build on our expertise in using sputum as a sample for flow cytometric analysis, including research to detect the presence of specific therapeutic targets to identify patients who can benefit from specific treatments.
International Patent Recognition: Received a Certificate of Grant of Patent from the Japan Patent Office for the Company’s unique method using flow cytometry to predict the likelihood of lung disease, including CyPath® Lung’s application for early-stage lung cancer detection.
2025 Financial Outlook

The Company anticipates generating between $6 million to $8 million in total revenue in 2025, including $1 to $2 million from sales of CyPath lung tests. The reduction in revenue for the 2025 financial outlook as compared to 2024 is a result of discontinuing certain unprofitable pathology services, which will be more than offset by corresponding cost reductions from lower labor and overhead costs at our subsidiary laboratory.

Recent Events

Case Studies: Released a series of patient case studies in collaboration with Gordon Downie, MD, PhD, Director of the Pulmonary Nodule Clinic at Titus Regional Medical Center in Texas. The studies illustrate the benefit of CyPath® Lung to both patients and clinicians, including earlier diagnosis of recurrent cancer and new primary lung cancer and avoiding unnecessary invasive procedures that carry risks for elderly patients with comorbidities.
FDA Pivotal Study: Submitted protocol for a pivotal clinical trial to the Sterling Institutional Review Board (IRB). Academic, private, military, and VA medical centers have been qualified as collection sites for an estimated 3,500-patient clinical trial expected to open in the second quarter of 2025.
Management Commentary

“We are proud of the tremendous strides bioAffinity Technologies made in 2024, achieving record revenue and laying the groundwork for continued growth,” bioAffinity President and Chief Executive Officer Maria Zannes said. “The full-year integration of our pathology lab, Precision Pathology, and the growing adoption of CyPath® Lung reflect the success of our strategy to build a scalable, high-impact business focused on early lung cancer detection.

“Our inclusion on the U.S. Federal Supply Schedule marks a major milestone, ensuring Veterans and military personnel across the country have easy access to CyPath® Lung,” Zannes continued. “Physician adoption is accelerating, driven by the clinical value and noninvasive nature of our test. Referrals and word-of-mouth continue to fuel our expansion beyond Texas, positioning us for sustained growth.”

“As we look to 2025, our focus remains on expanding commercial adoption of CyPath® Lung, strengthening our relationships with key opinion leaders, starting our FDA pivotal study, and advancing our pipeline of diagnostics powered by artificial intelligence and flow cytometry,” Zannes added. “With the recent streamlining of operations that will increase profitability at our laboratory, we are building a company with the science, strategy and leadership to shape the future of lung cancer diagnostics — and with every test ordered, we’re unlocking value for both patients and shareholders.”

2024 Financial Results

Revenue for the year ended December 31, 2024, was $9.4 million, compared with $2.5 million for the prior year. The increase was primarily driven by a full year of consolidated operations of Precision Pathology Laboratory Services, LLC (PPLS), which was acquired in September 2023. Revenue was primarily generated from patient service fees, including CyPath® Lung tests, and histology fees.

Operating expenses for 2024 totaled $18.3 million, compared with $10.5 million in 2023. The increase reflects the full-year impact of PPLS operations, higher sales and marketing activities, and increased general and administrative expenses associated with scaling commercial operations.

Direct costs and expenses were $6.0 million for 2024, up from $1.7 million in 2023, due to the inclusion of a full year of pathology and lab operations for PPLS. Research and development expenses remained level at approximately $1.5 million in both years, reflecting consistent investment in lab operations and preclinical development. Clinical development expenses also remained level at $0.3 million in both years. The Company expects to see an increase in clinical development expense in 2025, as enrollment begins for the FDA study.

Selling, general and administrative expenses were $9.9 million, compared with $6.8 million in 2023. The increase was mainly attributed to the expanded operations and personnel costs related to the commercialization of CyPath® Lung and a full year of operating PPLS.

Net loss for the year ended December 31, 2024, was $9.0 million, or $0.75 per share, compared with a net loss of $7.9 million, or $0.91 per share, for the prior year.

Cash and cash equivalents as of December 31, 2024, were $1.1 million, compared with $2.8 million as of December 31,

[glenn1919]

BIAF.........................................................a/h

[knrorrel]

BOOOOOOOOOOOM

[knrorrel]

some $BIAF add. , looks like next RUNNER tmr. , imo

[georgie18]

BIAF...8467...🥳...Moving up slowly off my 7099 Alert...10 Million range Float...

georgie18

Member Level
Re: georgie18 post# 672639

Tuesday, January 28, 2025 7:23:15 PM

Post#
672665
of 672673
BIAF...825...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 158

Tuesday, January 28, 2025 3:15:10 PM

Post#
159
of 159
BIAF...8026...🥳...Creeping up slowly...Off my .7099 Alert...

georgie18

Member Level
Re: georgie18 post# 672585

Tuesday, January 28, 2025 2:17:36 PM

Post#
672625
of 672638
BIAF...776...Hit 828 HOD...🥳...Bullish Psar Flip ...off my 7099Alert...

georgie18

Member Level
Re: georgie18 post# 156

Tuesday, January 28, 2025 9:44:48 AM

Post#
157
of 157
BIAF...7102...17K bidding @ 71 at top ask...🥳

georgie18

Member Level
Re: None

Monday, January 27, 2025 9:20:49 AM

Post#
672465
of 672584
BIAF...7099...🥳... https://schrts.co/gisRMsGc ...Watching for entry...10 Million range Float...

[georgie18]

BIAF...825...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 158

Tuesday, January 28, 2025 3:15:10 PM

Post#
159
of 159
BIAF...8026...🥳...Creeping up slowly...Off my .7099 Alert...

georgie18

Member Level
Re: georgie18 post# 672585

Tuesday, January 28, 2025 2:17:36 PM

Post#
672625
of 672638
BIAF...776...Hit 828 HOD...🥳...Bullish Psar Flip ...off my 7099Alert...

georgie18

Member Level
Re: georgie18 post# 156

Tuesday, January 28, 2025 9:44:48 AM

Post#
157
of 157
BIAF...7102...17K bidding @ 71 at top ask...🥳

georgie18

Member Level
Re: None

Monday, January 27, 2025 9:20:49 AM

Post#
672465
of 672584
BIAF...7099...🥳... https://schrts.co/gisRMsGc ...Watching for entry...10 Million range Float...

[georgie18]

BIAF...8026...🥳...Creeping up slowly...Off my .7099 Alert...

georgie18

Member Level
Re: georgie18 post# 672585

Tuesday, January 28, 2025 2:17:36 PM

Post#
672625
of 672638
BIAF...776...Hit 828 HOD...🥳...Bullish Psar Flip ...off my 7099Alert...

georgie18

Member Level
Re: georgie18 post# 156

Tuesday, January 28, 2025 9:44:48 AM

Post#
157
of 157
BIAF...7102...17K bidding @ 71 at top ask...🥳

georgie18

Member Level
Re: None

Monday, January 27, 2025 9:20:49 AM

Post#
672465
of 672584
BIAF...7099...🥳... https://schrts.co/gisRMsGc ...Watching for entry...10 Million range Float...

[georgie18]

BIAF...776...Hit 828 HOD...🥳...Bullish Psar Flip ...off my 7099Alert...

georgie18

Member Level
Re: georgie18 post# 156

Tuesday, January 28, 2025 9:44:48 AM

Post#
157
of 157
BIAF...7102...17K bidding @ 71 at top ask...🥳

georgie18

Member Level
Re: None

Monday, January 27, 2025 9:20:49 AM

Post#
672465
of 672584
BIAF...7099...🥳... https://schrts.co/gisRMsGc ...Watching for entry...10 Million range Float...

[georgie18]

BIAF...7102...17K bidding @ 71 at top ask...🥳

georgie18

Member Level
Re: None

Monday, January 27, 2025 9:20:49 AM

Post#
672465
of 672584
BIAF...7099...🥳... https://schrts.co/gisRMsGc ...Watching for entry...10 Million range Float...

[georgie18]

BIAF...7099...🥳... https://schrts.co/gisRMsGc ...Watching for entry...10 Million range Float...

[glenn1919]

BIAF.............................https://stockcharts.com/h-sc/ui?s=BIAF&p=W&b=5&g=0&id=p86431144783

[glenn1919]

BIAF.......................................https://stockcharts.com/h-sc/ui?s=BIAF&p=W&b=5&g=0&id=p86431144783

[Monksdream]

BIAF under $2

[glenn1919]

BIAF.................................https://stockcharts.com/h-sc/ui?s=BIAF&p=W&b=5&g=0&id=p86431144783

[Monksdream]

BIAF under $3

[Monksdream]

It does at that

[Sirpeter]

Bought some this morning...looks good

[glenn1919]

BIAF.............................https://stockcharts.com/h-sc/ui?s=BIAF&p=W&b=5&g=0&id=p86431144783

[Monksdream]

BIAF under $3

[glenn1919]

BIAF.............................................https://stockcharts.com/h-sc/ui?s=BIAF&p=W&b=5&g=0&id=p86431144783

[Monksdream]

BIAF new 52 week high

[Monksdream]

BIAF under $2

[Monksdream]

BIAF under $2

[Clean]

Share count has only gone from 8.3M-8.5M since 2022. Not much warrant activity to work through either. Very surprised to see dilution has been minimal here. One would think this would get a pop soon...

Earnings supposedly on 5/15/23. Wondering how that $11.8M cash on hand is holding up.

Does seem like it could be building up to something. I guess time will tell.

[luckydude777]

Slowly gaining price ground.

[luckydude777]

Waiting patiently for an update on their trials.

[luckydude777]

MM's just took out some stop losses. NEVER use them on a company with this much potential!

[luckydude777]

She's starting to run on NITRO.

[luckydude777]

$2.65 - $2.75 looks to be support. One piece of decent news and this sweetheart will be above $5 in short order.

[luckydude777]

Picked up a bunch of shares under $2.50 earlier. This company has POTENTIAL!

[luckydude777]

$2.50ish looks to be the bottom. (Right now, anyway).

[Invest-in-America]

BIAF: An Astronaut buddy of mine --- on duty, up in the International Space Station --- just texted me a live film-clip of BIAF zooming by him, on its way to Planet JUPITER just now!! (See below.)

[Invest-in-America]

BIAF: See my latest DDAmanda 'CHART', just now, for (BIAF)!!!

[Invest-in-America]

BIAF: Hey, King EZ, I had to WAIT until it settled-down, but jumped-on some. Their (Medical) news today looks damn important for perhaps a long-term run here. GOOD LUCK!!
https://www.businesswire.com/news/home/20230124005372/en/bioAffinity-Technologies-Announces-Publication-of-Results-of-Clinical-Trial-in-Peer-Reviewed-Journal-Respiratory-Research

[makinezmoney]

$BIAF: Beat me by a minute........ WOooooooooooohhoooooooooooo


Now $2.30

Ohhhhhhhh yaaaaaaaaaaaaaa............. I see it


Also BIAFW


GO $BIAF

[tw0122]

Can it stay over $2
Nice news .. Noninvasive Test Developed Using Machine Learning Detects Early-Stage Lung Cancer with High Sensitivity and Specificity

bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced publication of “Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning” detailing results of the Company’s clinical trial for its non-invasive diagnostic CyPath® Lung in Respiratory Research, one of the leading peer-reviewed open access journals in the field of respiratory medicine.

CyPath® Lung showed 92% sensitivity and 87% specificity in high-risk patients who had nodules smaller than 20 millimeters or no nodules in the lung, with an area under the ROC curve of 94%. Overall, the test resulted in specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer. More than half of those in the cancer cohort had early Stage I or II lung cancer. CyPath® Lung detected multiple forms of cancer including adenocarcinoma, squamous cell carcinoma and small cell lung cancer.

“The fact that CyPath® Lung can accurately predict lung cancer at an early stage in patients with small nodules is particularly important. Findings of lesions between six and 20 millimeters as a result of lung cancer screening can lead to unnecessary invasive procedures or a ‘watchful waiting’ period for patients,” said Vivienne Rebel, MD, PhD, bioAffinity Chief Medical and Science Officer and Executive Vice President. “Our test is intended for use with patients who display these indeterminant nodules to increase the accuracy of lung cancer screening and provide certainty for patients and their physicians.”

“CyPath® Lung uses an automated flow-based approach combined with machine learning that can be put into routine lab use without requiring expert evaluation of samples or being subject to operator bias,” said Madeleine Lemieux, PhD, who is first author and led development of the automated analysis used in CyPath® Lung. “The entire sample is rapidly analyzed which ensures maximal sensitivity. The automated, numerical analysis captures complex interactions between lung cancer and the micro-environment to reliably predict the presence of lung cancer that would not be possible for even expert individuals to do from visual flow data.”

Before working with bioAffinity Technologies, Dr. Lemieux was a computational biologist at the Dana Farber Institute and Harvard Medical School. She has contributed to more than 40 publications leveraging data from high-throughput platforms. Dr. Lemieux and Dr. Rebel began their successful collaboration during their doctoral studies.

CyPath® Lung uses flow cytometry, a method able to interrogate individual cells in a fraction of a second, and automated analysis to identify parameters in sputum that are indicative of cancer. Unlike genomic or other molecular markers used in liquid biopsies, bioAffinity’s CyPath® technology does not collect genetic material for evaluation. Instead, CyPath® Lung analyzes the lung micro-environment and identifies whole cell populations that indicate cancer is present in the lung.

[Clean]

Insiders here have lost their honey pot... the complete lack of movement has wreaked havoc on their cost to borrow income.

I see a pop coming here soon. They will once again loan out all their shares on said pop and collect interest.

Then most likely they will take that interest and buyback at much lower prices, once they have driven the price down to new lows.

[Clean]

Correct me if I'm wrong but I see nothing in any prospectus keeping pre-ipo shareholders from selling SOME of their non-restricted securities. Also some of their restricted holdings will soon be vested and able to be exercised.

Per the investment prospectus, not all of the 6 million previously issued shares are restricted. Some of the stock options are "currently exercisable or exercisable within 60 days"

the last IPO Prospectus after certification states:

Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. In computing the number of shares beneficially owned by a person or entity and the percentage ownership of that person or entity in the table below, all shares subject to options and warrants were deemed outstanding if such securities are currently exercisable, or would vest based on service-based vesting conditions within 60 days of August 17, 2022. These shares were not deemed outstanding, however, for the purpose of computing the percentage ownership of any other person or entity.

https://sec.report/Document/0001493152-22-021392/

I mean I could be reading this wrong, but this would lead to me to expect to see more public market dilution adding to the float around October 16th-17th??? The number of OS shown by brokers is already incorrect.

From what I am reading I believe Dilution Tracker to be correct and the OS is now around 8.38 million shares, with insiders owning probably somewhere around 3 million of it.

[Clean]

I was not referring to the underwriters. Shorts are usually dealt with on a broker to broker and transfer agent basis. The underwriters just drive price action, exercise, and sell shares into the market. That is until their lockup period is up and then they are basically a shareholder like the rest of us, unless there is more issuance. I was mainly referring to the decrease in share availability not being reflected in the short interest. I did not screen shot shares available last week so I do no remember the exact number, but it was not 0.